Lipids in Health and Disease最新文献

{"title":"Intracellular cholesterol: new functions and therapeutic approaches in NSCLC EGFR-TKI resistance.","authors":"Linjuan Wang, Yue Qiu, Xiang Huang, Shimei Zhang, Min Zhao, Qiufang Chen","doi":"10.1186/s12944-025-02559-w","DOIUrl":"10.1186/s12944-025-02559-w","url":null,"abstract":"<p><p>Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have markedly enhanced survival rates among patients with advanced non-small cell lung cancer (NSCLC) exhibiting EGFR mutations. However, acquired resistance diminishes their therapeutic efficacy over time. Recent investigations have linked intracellular cholesterol with the emergence and advancement of various cancers. Elevated cholesterol levels could correlate with resistance to EGFR-TKIs in NSCLC. This review examines the association between cholesterol and EGFR-TKI resistance in NSCLC, with the objective of identifying more effective treatments and surmounting resistance.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"24 1","pages":"255"},"PeriodicalIF":3.9,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12312335/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144753736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peripheral blood metabolic profiles of chronic rhinosinusitis and their mediating role between obesity and disease.","authors":"Zengxiao Zhang, Shunke Li, Shizhe Zhou, Lin Wang, Xudong Yan, Longgang Yu, Yan Jiang","doi":"10.1186/s12944-025-02672-w","DOIUrl":"10.1186/s12944-025-02672-w","url":null,"abstract":"<p><strong>Background: </strong>Chronic rhinosinusitis (CRS) is increasingly linked to systemic inflammation, however, research on peripheral blood metabolic patterns in CRS patients remains limited. This study aimed to investigate peripheral blood metabolic profiles in eosinophilic CRS and non-eosinophilic CRS, while exploring the mediating role of metabolites in the relationship between body mass index and CRS.</p><p><strong>Methods: </strong>Clinical data were collected from 1,151 CRS patients and 814 healthy controls, classifying patients into eosinophilic CRS and non-eosinophilic CRS groups based on tissue eosinophil counts. Peripheral blood metabolic profiles were compared across different CRS endotypes and between CRS patients and healthy controls. Causal mediation analysis assessed the mediating effects of metabolites on the relationship between body mass index and CRS.</p><p><strong>Results: </strong>CRS patients exhibited distinct metabolic profiles, with dysregulated lipid metabolism characterized by increased triglycerides, free fatty acids, and lipoprotein(a), but patients with eosinophilic CRS had higher triglycerides, while non-eosinophilic CRS had higher free fatty acids. Cystatin-C effectively differentiated CRS endotypes (area under the curve = 0.735). Elevated body mass index was a risk factor for both eosinophilic CRS and non-eosinophilic CRS patients, with peripheral free fatty acids and Cystatin-C mediating this effect.</p><p><strong>Conclusions: </strong>This study reveals distinct metabolic profiles in patients with CRS, supporting its link to systemic inflammation. Promoting healthy dietary habits and weight control is therefore a cornerstone of sustainable, preventive care, offering a practical strategy to improve long-term patient well-being, particularly in refractory cases.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"24 1","pages":"251"},"PeriodicalIF":3.9,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306000/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144732072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rates of acute pancreatitis and cardiovascular events among adults with severe or extreme hypertriglyceridemia in US clinical practice.","authors":"Asia Sikora Kessler, Seth J Baum, Emily Kutrieb, Montserrat Vera Llonch, Alex Lonshteyn, Derek Weycker, Daniel E Soffer","doi":"10.1186/s12944-025-02658-8","DOIUrl":"10.1186/s12944-025-02658-8","url":null,"abstract":"<p><strong>Background: </strong>Severe and extreme hypertriglyceridemia (sHTG [TG 500-879 mg/dL; 5.65-9.93 mmol/L]; eHTG [TG ≥ 880 mg/dL; ≥ 9.94 mmol/L]) are important risk factors for acute pancreatitis (AP) and cardiovascular (CV) events. The objective of this study was to estimate rates of AP and CV events for adults with (and without) sHTG/eHTG in US clinical practice.</p><p><strong>Methods: </strong>A retrospective design and data from the MarketScan Research Databases were employed. Study population comprised adults with ≥ 1 TG value and was stratified by index TG (< 150, 150-499, 500-879, ≥ 880 mg/dL; < 1.69, 1.69-5.64, 5.65-9.93, ≥ 9.94 mmol/L). AP/CV events (per 1,000 person-years [PY]) were ascertained from index TG through end of study period, and were estimated for TG-specific subgroups and selected subsets defined therein.</p><p><strong>Results: </strong>Study population totaled 1.8 M adults (TG < 150 mg/dL [< 1.69 mmol/L]: N = 1.3 M; TG 150-499 mg/dL [1.69-5.64 mmol/L]: N = 449 K; TG 500-879 mg/dL [5.65-9.93 mmol/L]: N = 12,050; TG ≥ 880 mg/dL [≥ 9.94 mmol/L]: N = 3,944). AP rates (per 1,000 PY) increased from lowest to highest TG value (0.6 [< 150 mg/dL; < 1.69 mmol/L]) to 9.9 [≥ 880 mg/dL; ≥ 9.94 mmol/L]); rates were highest for adults with TG ≥ 880 mg/dL (≥ 9.94 mmol/L) and history of AP (193.0), pre-existing diabetes (13.9), or history of LLT (13.9). CV event rates (per 1,000 PY) also increased from lowest to highest TG value (3.3 [< 150 mg/dL; < 1.69 mmol/L]) to 10.3 [≥ 880 mg/dL; ≥ 9.94 mmol/L]); rates were highest for adults with TG ≥ 880 mg/dL (≥ 9.94 mmol/L) and history of CV events (116.5), pre-existing diabetes (18.1), or history of LLT (14.5).</p><p><strong>Conclusion: </strong>Rates of AP/CV events are substantially higher among adults with elevated TG values, and are especially high among adults with sHTG or eHTG, in particular those with these conditions and other risk factors. Understanding the magnitude of disease risk among sHTG/eHTG patients, with increasing TG levels as well as within important subgroups, is critical to improving patient care and outcomes.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"24 1","pages":"252"},"PeriodicalIF":3.9,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305886/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144732073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between visceral fat area and heart rate variability in high altitude migrants with OSA: the mediating effect of insulin resistance.","authors":"Shanshan Jia, Yongxing Fu, Yong Wu, Hongwei Li, Doudou Hao, Yunhong Wu, Xiaoping Chen, Liming Zhao","doi":"10.1186/s12944-025-02626-2","DOIUrl":"10.1186/s12944-025-02626-2","url":null,"abstract":"","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"24 1","pages":"253"},"PeriodicalIF":3.9,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306044/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144732071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of lipoprotein(a) variability in clinical practice and their impact on cardiovascular risk.","authors":"Hyung Joon Joo, Seung Gyu Yun, Jae Hyoung Park, Soon Jun Hong, Cheol Woong Yu, Seung Yong Shin, Eung Ju Kim","doi":"10.1186/s12944-025-02666-8","DOIUrl":"10.1186/s12944-025-02666-8","url":null,"abstract":"<p><strong>Background: </strong>Lipoprotein(a) (Lp[a]) is an established cardiovascular risk marker; however, its intraindividual variability and implications for risk stratification remain poorly understood. This study investigated the clinical and biochemical predictors of high Lp(a) levels and evaluated their potential roles in cardiovascular risk assessment to inform evidence-based public health strategies for cardiovascular disease prevention.</p><p><strong>Methods: </strong>This retrospective multicenter observational study was conducted using data from three tertiary university hospitals in Korea. Patients with at least two Lp(a) measurements taken ≥ 90 days apart were included (n = 5,305). High Lp(a)-level variability was defined as an absolute change of > 10 mg/dL and a relative change of > 25%. Predictors of high-variability were identified through regression analyses, and risk reclassification across Lp(a) risk categories was performed.</p><p><strong>Results: </strong>Baseline and follow-up Lp(a) levels were strongly correlated (r = 0.89, P < 0.01); however, substantial individual variability was observed, with a median absolute change of 3.9 mg/dL and a median percentage change of 26.3%. Approximately 19.9% of the patients exhibited high Lp(a) level variability, which was associated with lower baseline Lp(a) levels and higher follow-up Lp(a) levels, lower body mass indices, higher hemoglobin levels, elevated white blood cell and platelet counts, increased serum glucose levels, lower high-density lipoprotein cholesterol levels, and use of antihypertensive medications. Notably, risk reclassification analysis revealed marked variability among patients in the intermediate \"gray-zone.\"</p><p><strong>Conclusions: </strong>The findings of this study indicate that Lp(a) level variability is associated with adverse cardiovascular risk profiles and dynamic risk reclassification. These results highlight the potential of serial Lp(a) measurements to refine cardiovascular risk stratification, particularly in intermediate-risk patients. Integrating these findings into clinical practice guidelines has the potential to improve cardiovascular risk management at the population level, reduce healthcare disparities, and inform targeted public health interventions aimed at cardiovascular prevention.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"24 1","pages":"250"},"PeriodicalIF":3.9,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12288285/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiply doses of FDC of rosuvastatin and ezetimibe versus rosuvastatin monotherapy in Chinese patients with hypercholesterolemia (ROSE-CH): multicenter, randomized-controlled trial.","authors":"Xianyou Ji, Jinlan Xia, Hong Zhang, Changjie Ren, Guang Ma, Shenwen Fu, Jun Zhang, Ying Chen, Xuebin Han, Jianming Zhang, Zhengxu Fang, Bo Yang, Baisong Yang, Wenjun Huang, Gang Yin, Hong Qi, Hao Gong, Dongfang Wang, Liuyi Hao, Xiufeng Zhao, Zhaohui Pei, Peijian Wang, Xiaodong Li, Ling Lin, De Li, Zhi Li, Lin Zhang, Bo Yin, Ying Cheng, Zhiqing You, Jianlong Sheng, Jie Wu, Ling Chen, Zhongcai Fan, Wang Zhao, Shuiping Zhao","doi":"10.1186/s12944-025-02670-y","DOIUrl":"10.1186/s12944-025-02670-y","url":null,"abstract":"<p><strong>Objective: </strong>Rosuvastatin plus ezetimibe improves the lipid-lowering effect through different mechanisms of action. This study intended to compare the efficacy and safety of the fixed-dose combination (FDC) of rosuvastatin/ezetimibe vs. rosuvastatin alone in hypercholesterolemia patients.</p><p><strong>Methods: </strong>ROSE-CH (ROSuvastatin and Ezetimibe in Chinese Hypercholesterolemia patients) was a multicenter, randomized, double-blind, positive drug-controlled, superiority-tested phase III clinical trial; 743 patients were randomized into rosuvastatin/ezetimibe 10/10 mg, 5/10 mg, and 2.5/10 mg groups, as well as rosuvastatin 10 mg and 5 mg groups at a 1:1:1:1:1 ratio. A total of 143, 127, 263, and 137 patients had low, intermediate, high, and very-high baseline atherosclerotic cardiovascular disease (ASCVD) risks. The study period spanned from December 24, 2021, to December 6, 2022.</p><p><strong>Results: </strong>Efficacy and safety assessments were conducted in 670 and 696 patients. Percentage change in low-density lipoprotein cholesterol (LDL-C) from baseline to week (W)12 was greater in the rosuvastatin/ezetimibe 10/10 mg group vs. rosuvastatin 10 mg group [least-squares means (LSmean): -51.48% vs. -42.47%], rosuvastatin/ezetimibe 5/10 group vs. rosuvastatin 5 mg group (LSmean: -50.08% vs. -40.17%), and rosuvastatin/ezetimibe 2.5/10 mg group vs. the rosuvastatin 5 mg group (LSmean: -48.47% vs. -40.17%) (all P < 0.001). The same trend was observed for the percentage change in LDL-C from baseline to W4 and W8 (all P < 0.001). In patients with baseline very high ASCVD risk, the achievement of LDL-C target at W12 was higher in rosuvastatin/ezetimibe 10/10 mg vs. rosuvastatin 10 mg groups and rosuvastatin/ezetimibe 2.5/10 mg vs. rosuvastatin 5 mg groups (both P < 0.05). The incidence of adverse events was 36.0%, 38.7%, 25.2%, 31.4%, and 38.6% in each group. Regarding serious adverse events, the incidence was 2.2%, 2.9%, 0.7%, 3.6%, and 0.7% in each group. The incidence of drug-related adverse events was relatively high, which was 26.6%, 31.4%, 18.5%, 23.6%, and 29.0% in each group, respectively, irrespective of the absence of serious drug-related adverse events.</p><p><strong>Conclusion: </strong>The FDC of rosuvastatin/ezetimibe has superior LDL-C-lowering effects over rosuvastatin alone, with good safety profiles in hypercholesterolemia patients.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"24 1","pages":"249"},"PeriodicalIF":3.9,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12281852/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Lipid droplet accumulation in microglia and their potential roles.","authors":"Yunxia Li, Qi Zhao, Yan Wang, Wenyi Du, Riyun Yang, Jian Wu, Yi Li","doi":"10.1186/s12944-025-02665-9","DOIUrl":"10.1186/s12944-025-02665-9","url":null,"abstract":"","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"24 1","pages":"247"},"PeriodicalIF":3.9,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12281718/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of treatment patterns, efficacy and safety between generic and branded atorvastatin users in China: a multicenter, retrospective propensity score-matched cohort study.","authors":"Xiaoxuan Xing, Zhizhou Wang, Ke Wang, Yiming Hua, Xiaoxi Li, Kejia Le, Wenbing Ma, Yingyun Guan, Aiping Deng, Xiong Yun, Hongfu Cai, Yongning Lyu, Guoying Xiong, Min Yang, Siyang Wang, Chaojun Xue, Jing Zhang, Qiushi Guo, Song Hu, Jing Li, Xianzhe Dong, Lan Zhang","doi":"10.1186/s12944-025-02673-9","DOIUrl":"10.1186/s12944-025-02673-9","url":null,"abstract":"<p><strong>Background: </strong>To evaluate and compare the treatment patterns, effectiveness, and safety of generic and branded atorvastatin in China.</p><p><strong>Methods: </strong>This multicenter, retrospective cohort study collected and analyzed data from patients who initiated atorvastatin therapy for the first time across 16 hospitals between 2020 and 2022. Treatment patterns included adherence, persistence, switching, augmentation. Absolute reductions of low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol, total cholesterol, and triglycerides, LDL-C reduction ≥ 50%, and adverse events were assessed to measure efficacy and safety. Propensity score matching was utilized to control for potential confounding variables.</p><p><strong>Results: </strong>Data of 359,159 patients were reviewed. The results indicated a greater proportion of patients the generic atorvastatin group (5772/39742 [14.5%]) exhibited good adherence compared to those in the branded atorvastatin group (3157/39742 [7.9%]; P < 0.001) with an odds ratio of 1.97 (95% CI 1.88-2.06; P < 0.001). In the generic atorvastatin group, a smaller proportion of patients discontinued treatment (35,621/39,742 [89.6%]) compared to the branded group (36,390/39742 [91.6%]; P < 0.001) This difference in treatment persistence was further reflected in the calculated hazard ratio, which was 0.85 (95% CI 0.84-0.86; P < 0.001), indicating a reduced risk of discontinuation in the generic group. Efficacy outcomes were comparable between two groups (all P > 0.05). Both groups exhibited a comparable incidence of most adverse events. Less fasting plasma glucose increase and fewer new-onset diabetes were observed in the generic group (0.01 mmol/L [IQR 0-0.58] vs 0.16 mmol/L [IQR 0-0.73]; P = 0.009; 664/28640 [2.3%] vs 1244/28640 [4.3%]; P < 0.001).</p><p><strong>Conclusion: </strong>Generic atorvastatin had higher adherence and persistence and lower costs vs the branded drug, with no significant differences in efficacy and safety. Generic atorvastatin can be considered a viable option for dyslipidemia and atherosclerotic cardiovascular disease.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"24 1","pages":"248"},"PeriodicalIF":3.9,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12281942/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of hepatic biomarkers with incident diabetes: a mediation analysis of the triglyceride-glucose index in a large Chinese cohort.","authors":"Baoyin Li, Tao Liu, Zhijian Zhu, Bing Wang, Zhigang Lu, Yesheng Pan","doi":"10.1186/s12944-025-02661-z","DOIUrl":"10.1186/s12944-025-02661-z","url":null,"abstract":"<p><strong>Background: </strong>Diabetes disproportionately impacts low- and middle-income populations, exacerbating existing health disparities. The role of hepatic biomarkers, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), and the ALT/AST ratio, in predicting diabetes onset remains insufficiently elucidated. This research assessed how these biomarkers relate to diabetes risk, as well as assessed the mediating effect of the triglyceride-glucose (TyG) index.</p><p><strong>Methods: </strong>The secondary analysis utilized data from the Dryad public database, encompassing a cohort of 211,833 Chinese adults aged ≥ 20 years who underwent health examinations between 2010 and 2016. After applying rigorous exclusion criteria, 50,463 participants were included. Cox proportional hazards models were applied to examine how hepatic biomarkers and the TyG index influenced diabetes incidence. The mediation analysis was conducted to assess the TyG index's contribution to the hepatic biomarker-diabetes relationship.</p><p><strong>Results: </strong>Throughout the observational phase (mean 3.08 years), 1309 participants (2.59%) established diabetes. Increased levels of ALT, AST, and the ALT/AST ratio were all significantly related to a heightened diabetes risk, with the most significant correlation noted for the ALT/AST ratio (adjusted HR per unit increase: 1.04; 95% CI: 1.02-1.05; P < 0.001). Participants in the highest quartile of the ALT/AST ratio had nearly three times the risk of diabetes than the lowest quartile (HR: 2.94; 95% CI: 2.42-3.57; P < 0.001). Joint analysis revealed synergistic effects between elevated hepatic biomarkers and the TyG index, with the combination of high ALT/AST ratio and elevated TyG index yielding the greatest risk (HR: 5.23; 95% CI: 4.42-6.18; P < 0.001). The mediation analysis showed that the TyG index significantly mediated the associations, accounting for 40.25%, 36.45%, and 76.97% of the effects of ALT, AST, and the ALT/AST ratio, respectively, on diabetes risk.</p><p><strong>Conclusion: </strong>Hepatic biomarkers, particularly the ALT/AST ratio, robustly predict diabetes risk in this large cohort, with the TyG index explaining most of this association. These insights reinforce the importance of integrating hepatic and metabolic assessment in preventive strategies to address the growing diabetes epidemic.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"24 1","pages":"246"},"PeriodicalIF":3.9,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-density lipoprotein cholesterol, particles and subspecies and the risk of chronic kidney disease: The PREVEND prospective study.","authors":"Setor K Kunutsor, Margery A Connelly, Stephan J L Bakker, Robin P F Dullaart","doi":"10.1186/s12944-025-02668-6","DOIUrl":"10.1186/s12944-025-02668-6","url":null,"abstract":"<p><strong>Background: </strong>The relationships between high-density lipoprotein cholesterol (HDL-C), HDL particle concentration (HDL-P), and HDL subspecies with the development of chronic kidney disease (CKD) have not been well characterized. This study aimed to examine these associations and evaluate the role of alcohol consumption as a potential confounder or effect modifier.</p><p><strong>Methods: </strong>Data was analyzed from 4,179 individuals (mean age: 52 years; 47.6% male) participating in the PREVEND cohort. Baseline measurements included HDL-P and its subfractions (small, medium, and large), quantified by nuclear magnetic resonance spectroscopy, and self-reported alcohol intake. Incident CKD was defined using criteria from the KDIGO guidelines. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for each HDL metric per 1 standard deviation (SD) increment.</p><p><strong>Results: </strong>Over a median follow-up of 8.3 years, 565 participants developed CKD. After adjusting for multiple confounders, including alcohol use, HDL-P, medium HDL, and H3P showed modest inverse associations with CKD risk, with adjusted HRs (95% CIs) of 0.90 (0.83-0.98), 0.91 (0.83-1.00), and 0.90 (0.82-0.99), respectively. Conversely, H7P was positively associated with CKD risk (HR 1.11, 95% CI: 1.00-1.22). Significant interactions with sex were observed for medium HDL, small HDL, and H1P. Alcohol intake neither significantly modified the associations nor showed a direct relationship with CKD risk.</p><p><strong>Conclusions: </strong>This study suggests distinct associations of HDL parameters with CKD risk as well as sex differences in the associations of these parameters with CKD risk. The findings underscore the heterogeneity of HDL subspecies and the need to consider sex-specific differences in future studies. Alcohol consumption had no impact on these associations.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"24 1","pages":"245"},"PeriodicalIF":3.9,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12275243/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}